Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits  by Tanaka, Etsuro et al.
Vascular endothelial growth factor (VEGF) is anendothelial cell–specific mitogen that promotes
angiogenesis.1,2 Four different VEGF transcripts encod-
ing polypeptides of 206, 189, 165, and 121 amino acids
are expressed by human cells. Administration of
VEGF165 caused angiogenesis in ameroid-induced
ischemia in canine3 and porcine4 hearts. Gene therapy
has the potential to induce protein expression, and ade-
noviral vectors have provided high-yield gene transfers
to the heart.5 Mack and associates6 demonstrated the
usefulness of gene therapy for ameroid-induced cardiac
ischemia by direct intramuscular administration of an
adenovirus vector expressing VEGF121 in swine, and
similar results have been reported for intracoronary
gene transfer of fibroblast growth factor 5.7 In the pres-
ent study, we evaluated the effects of gene therapy in a
model of microvascular ischemia. Microvascular
myocardial ischemia is an example of intractable
myocardial ischemia,8 since neither percutaneous trans-
Objectives: Restoration of coronary blood flow by angiogenesis may offer a
new approach to intractable ischemic heart disease. In the present study, we
investigated the angiogenic effects of gene transfer of vascular endothelial
growth factor 165 on microvascular myocardial ischemia. 
Methods: A rabbit model of microvascular myocardial ischemia was created
by plugging coronary microvessels with microspheres (15 µm in diameter,
2.8 × 105/kg, n = 29). Gene transfer was performed by semi-selective intra-
coronary injection of recombinant adenovirus expressing vascular endothe-
lial growth factor 165 forty minutes after microsphere injection (n = 9).
Results: Microsphere injection reduced myocardial perfusion (78% ± 9% of
baseline tissue flow) and diminished myocardial contraction (61% ± 12% of
the baseline ejection fraction) and cardiac performance (elevated left ven-
tricular end-diastolic pressure and decreased systemic flow) in the acute
phase. At 17 ± 3 days, gene transfer of vascular endothelial growth factor
165 had had the following effects: (1) promoted coronary angiogenesis as
evidenced by myocardial flow above the baseline (121% ± 24%), (2)
increased vascular density revealed by synchrotron radiation microangiogra-
phy and histologic analysis, (3) ameliorated the degree of myocardial
ischemia as evidenced by myocardial lactate content and the extent of histo-
logic necrosis, and (4) restored heart function as evidenced by increased
ejection fraction (95% ± 10%), reduced left ventricular end-diastolic pres-
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Conclusions: In vivo vascular endothelial growth factor 165 gene transfer
promoted angiogenesis and was an effective approach to treating microvas-
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luminal coronary angioplasty nor coronary artery
bypass grafting can be used to treat small segments of
the epicardial coronary arteries having a diameter of
less than 1 mm or intramural coronary vessels. In this
study, we created microvascular myocardial ischemia
in rabbits by plugging coronary beds with 15 µm
microspheres. This model is characterized by sustained
nonnecrotic myocardial ischemia lasting more than 2
months.9,10 We evaluated the effects of gene transfer by
intracoronary injection of recombinant adenovirus
expressing VEGF165 (Ad-VEGF) and lacZ (Ad-lacZ)
on this microvascular ischemia model.
Methods
This investigation was carried out in conformity with the
“Guide for the Care and Use of Laboratory Animals” pub-
lished by the National Institutes of Health (NIH publication
No. 86-23, revised 1985). All procedures were performed
with the animals under general anesthesia, that is, after intra-
venous injection of sodium pentobarbital (30 mg/kg). 
Experimental protocols. Forty-six Japanese White rabbits
weighing 3.57 ± 0.46 kg (Tokyo Laboratory Animal Science
Co, Ltd, Tokyo, Japan) were used. In 39 of the rabbits,
microvascular ischemia was created by injecting indium-
labeled microspheres having a diameter of 15 µm, and the
remaining 7 rabbits were used to obtain normal standards for
the metabolic or histologic indices. The ischemic rabbits (n =
39) were further divided into 3 groups as follows. After micro-
sphere injection, the hearts of 18 rabbits were injected with
saline solution (sham-1 group), the hearts of 8 rabbits were
injected with 6 × 109 plaque-forming units (pfu) of Ad-lacZ
(sham-2 group), and the hearts of the remaining 13 rabbits were
injected with 6 × 109 pfu of Ad-VEGF (VEGF group). Twenty-
nine of the 39 ischemic rabbits were killed 14 to 21 days (mean,
17 days) after microsphere injection, and 10 rabbits were killed
4 days after the injection to confirm the delivered gene.
A 3F catheter was placed in the right femoral artery to
record aortic pressure and to obtain reference blood samples
for measurement of regional blood flow during microsphere
injection. The tip of a 4F catheter was positioned in the left
ventricle via the right common carotid artery to record left
ventricular pressure and to inject microspheres and ade-
novirus. The tip of a 4F Fogarty balloon catheter (Baxter
Healthcare, Inc, Irvine, Calif) was positioned in the thoracic
descending aorta via the left femoral artery to obstruct aortic
blood flow by balloon inflation. During balloon inflation, we
confirmed that femoral artery pressure was less than 20 mm
Hg. The injections of indium-labeled microspheres for coro-
nary artery plugging and for virus solution were terminated
within 40 seconds, but balloon inflation and temporary liga-
tion of the left common carotid artery were maintained until
70 seconds after the start of the injection. Under these condi-
tions, blood flow to the abdominal organs and lower extrem-
ities was substantially interrupted by balloon inflation, and
blood flow to the head was interrupted by bilaterally occlud-
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ing the common carotid arteries (blood flow via the vertebral
arteries was left intact). Comparison between the relative ele-
mental activity ratio (heart/kidney) of barium-labeled micro-
spheres for flow measurement (0.72 ± 0.33) and indium-
labeled microspheres for coronary plugging (7.30 ± 3.57)
indicated high selectivity (approximately 10-fold difference)
of our method for microvascular plugging and gene delivery
in the heart.
The microspheres (15 µm in diameter) were labeled with
one of four sets of stable heavy elements (indium, iodine,
barium, or cerium; Sekisui Plastic, Osaka, Japan)11 and
suspended in 0.05% sodium dodecyl sulfate at a concentra-
tion of 5.0 × 105/mL. The indium-labeled microspheres
(2.8 × 105/kg) were gently injected into the left ventricle in
3 doses at 10-minute intervals to plug the coronary artery
system of the heart. X-ray fluorescence of indium indicat-
ed the degree of plugging of arterioles having a diameter of
15 µm. There were no significant differences among the 3
groups: 178 ± 88, 169 ± 68, and 193 ± 132 counts · s–1 · g–1
in the sham-1 (n = 11), sham-2 (n = 6), and VEGF groups
(n = 6), respectively. In one series of preliminary experi-
ments, administration of 5.0 × 105/kg indium-labeled
microspheres to 2 rabbits resulted in the death of both with-
in 2 days (100%), and administration of 3.75 × 105/kg to 5
rabbits resulted in the death of 4 of them (80%). Even
injection of the dose used in this study (2.8 × 105/kg) led to
the death of 9 of the 54 rabbits (17%) within 2 days. In the
other series of preliminary experiments in rabbits, we
detected diffuse extensive reduced nicotinamide adenine
dinucleotide (NADH) fluorescence of myocardium at 16
days after the microsphere injection. NADH fluorescence
is from ischemic cells, but not intact or infarcted cells.12
Therefore, this indicated a sustained ischemia lasting for at
least 16 days. In similar canine experiments,9,10 substantial
NADH fluorescence was noted 2 months after microsphere
injection into the coronary arteries.
Forty minutes after completion of the indium-labeled
microsphere injection, adenovirus-containing saline solu-
tion (2 mL) or pure saline solution (2 mL) was injected into
39 animals in the same manner as in the indium-labeled
microspheres. Ten minutes before (baseline) injection of
the indium-labeled microspheres, and 10 minutes after
(acute phase), barium- and iodine-labeled microspheres
(1.25 × 105/kg), respectively, were injected without balloon
inflation to measure blood flow in the major organs. Two-
dimensional and M-mode echocardiographic images (SSD-
630; Aloka Co, Ltd, Mitaka, Japan) were obtained via a
right parasternal approach to determine the ejection frac-
tion. Cerium-labeled microsphere injection to measure
regional blood flow and echocardiographic measurements
were repeated 17 ± 3 days after induction of ischemia
(chronic phase). After the animals had been killed, their
major organs were dissected out, and the x-ray fluores-
cence of each heavy element was measured to calculate
regional blood flow.11 Lactate content in the left ventricle
was also evaluated after the myocardium was frozen quick-
ly with liquid nitrogen.13 Arteriolar density was evaluated
as the number of intramyocardial arterioles in the left ven-
tricle14,15 (the free wall and the interventricular septum) by
blinded analysis (alkaline phosphatase staining).16 Two
investigators blinded to treatment graded histologic evi-
dence of infarction in each tissue section stained with azan
and hematoxylin-eosin on a scale of 0 to 3 as follows: 0 =
none; 1 = mild (less than 5% of the section surface); 2 =
moderate (more than 5%, up to 20% of the section surface);
and 3 = severe (more than 20% of the section surface).
Expression of lacZ was determined 4 days after transfec-
tion by X-Gal histologic staining as previously reported17
in 2 rabbits in the sham-2 group. VEGF expression was
quantified 4 days after transfection with the Quantikine
human VEGF immunoassay (R&D Systems, Inc,
Minneapolis, Minn) in 8 rabbits in the sham-1 (n = 4) and
VEGF groups (n = 4). Tissue samples (0.5 g) were homo-
genized and protein determinations were performed in
duplicate according to the methods of Magovern and asso-
ciates.18 The standard wells against which the samples were
compared contained equal amounts of normal rabbit tissue
homogenate to correct for any background that might inter-
fere with the absorbance.19 The concentration of VEGF was
normalized to milligrams of protein.
Coronary angiography. In 6 ischemic rabbits (3 in the
sham-1 group and 3 in the VEGF group), synchrotron radia-
tion angiography was performed as previously de-
scribed.20,21 In brief, monochromatic synchrotron radiation
with an energy level of 33.3 keV was used as the x-ray
source, and contrast images of the object were formed on a
high-sensitivity fluorescent screen (FOS; Hamamatsu
Photonics Co, Hamamatsu, Japan), which was scanned at 30
frames/s by a high-definition television camera with 1125
television lines (New Super HARP; NHK, Tokyo, Japan).
This system is capable of separating adjacent lead lines only
25 µm apart on the resolution bar chart. Sixteen or 17 days
after induction of ischemia, a 4F catheter was placed near the
aortic valve in the ascending aorta via the left carotid artery,
and contrast material containing 37% nonionic iodine
(iopamidol; Nihon Schering Co Ltd, Tokyo, Japan) was
injected. Morphometric angiographic analysis of collateral
vessel development was performed as previously
described.21 In brief, a composite of 0.5 × 0.5 mm grids was
placed over the thigh area of the angiogram. The total num-
ber of grid intersections and the total number of intersections
crossed by a contrast-opacified artery were counted individ-
ually by a single observer blinded to the treatment regimen.
An angiographic score was calculated for each animal as the
ratio of grid intersections crossed by opacified arteries divid-
ed by the total number of grid intersections.
Recombinant adenoviral vectors. Replication-defective
E1 and E3 adenoviral vectors expressing either human
VEGF16522 (Ad-VEGF) or β-galactosidase (Ad-lacZ) under a
CA promoter comprising a cytomegalovirus enhancer and
chicken β-actin promoter23 were prepared by in vitro homol-
ogous recombination in a 293-cell assay system, as previous-
ly described.17,24 The desired recombinant adenovirus was
purified by ultracentrifugation through a CsCl2 gradient fol-
lowed by extensive dialysis. Contamination of wild-type ade-
novirus was excluded by polymerase chain reaction designed
for E1 amplification.17 The titer of the virus stock was
assessed by a plaque-formation assay with the 293-cell sys-
tem and expressed as plaque-forming units.24
Statistical analysis. Data are presented as mean values ±
SD. Differences between means were assessed by the paired
t test, Wilcoxon signed rank sum test, Mann-Whitney test, or
analysis of variance for factorial or repeated measures with
the Scheffé F test when applicable.
Results
Functional effects of intracoronary injection of
microspheres in the acute phase (data from the 3
groups). Microsphere injection reduced myocardial
perfusion (78% ± 9% of baseline tissue flow), dimin-
ished myocardial contraction (61% ± 12% of the base-
line ejection fraction), and cardiac performance (ele-
vated left ventricular end-diastolic pressure [LVEDP]
and decreased systemic flow [renal and cerebral flow])
in the acute phase. The absolute values of these indices
in each group are shown in the baseline and acute phase
lines in Table I, and they were not significantly differ-
ent among the 3 groups.
Amelioration of myocardial ischemia with Ad-
VEGF. After 17 ± 2 days, intracoronary injection of
Ad-VEGF had promoted coronary angiogenesis as evi-
denced by myocardial flow above the baseline,
increased vascular density as observed by microan-
giography and histologic analysis, ameliorated the
degree of myocardial ischemia as evidenced by
myocardial lactate content and the extent of histologic
necrosis, and restored heart function as evidenced by
LVEDP reduction, increased ejection fraction, and
body weight restoration. These indices are summarized
in Table I.
Ad-VEGF promoted angiogenesis in the myocardium,
as indicated by the regional blood flow measurements,
microangiograms, and histologic analysis (ANOVA). In
the chronic phase (17 days after induction of ischemia),
myocardial blood flow surpassed its baseline value
(121% ± 24%) in the VEGF group but was not restored
to the baseline (92% ± 14% and 87% ± 15%) in the sham
groups. The absolute myocardial flow value in the VEGF
group (2.95 ± 0.23 mL · min–1 · g–1) significantly exceed-
ed the values in the 2 sham groups (2.22 ± 0.42 and 2.24
± 0.23 mL · min–1 · g–1, P < .05, ANOVA). Synchrotron
radiation coronary microangiography showed that the
peripheral coronary arteries (90-510 µm in diameter)
became more prominent in the VEGF gene–treated rab-
bits than in the sham rabbits and that localized dense con-
trast regions were occasionally noted in the former (Fig
1). These changes are probably due to enhancement of
regional blood flow evoked by the angiogenic action of
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the transferred VEGF gene. Histologic examination
demonstrated other evidence of enhanced angiogenesis in
the VEGF group. The number of intramyocardial arteri-
oles (20-100 µm in diameter) was increased approxi-
mately 2-fold by Ad-VEGF treatment (P < .05, ANOVA,
Table I, Fig 2, A and B). 
Metabolic evaluation and histologic analysis revealed
that Ad-VEGF ameliorated the degree of myocardial
ischemia. The myocardial lactate content in the VEGF
group was restored to a level similar to the normal stan-
dard by the end of the experiment, and the levels in
these 2 groups were significantly lower than in the 2
Table I.  Effects of intracoronary injection of microspheres and recombinant adenovirus expressing lacZ and
VEFG165
Ischemic rabbits (n = 29)
Normal standard rabbits Sham-1 Sham-2 VEGF
(n = 7) (n = 14) (n = 6) (n = 9)
Chronic phase (d) 16.9 ± 2.3 (7) 16.9 ± 4.4 (11) 16.7 ± 2.9 (6) 16.8 ± 2.1 (6)
Myocardial circulation
Myocardial blood flow 
(mL · min–1 · g–1) Baseline 2.48 ± 0.62 (11) 2.64 ± 0.48 (6) 2.48 ± 0.30 (6)
Acute phase 1.94 ± 0.44* 2.00 ± 0.30* 1.87 ± 0.26*
Chronic phase 2.22 ± 0.42 2.24 ± 0.23* 2.95 ± 0.23*†§
Percent change 92% ± 14% 87% ± 15% 121% ± 24%§
Arteriolar density 
(/mm2) Chronic phase 1.17 ± 0.40 (7) 1.55 ± 0.53 (14) 1.30 ± 0.43 (6) 2.73 ± 0.90 (9)‡§
Angiographic score Chronic phase 0.55 ± 0.07 (3) 0.76 ± 0.05 (3)§
Myocardial metabolism
Lactate content (mg/g) Chronic phase 0.58 ± 0.06 (7) 1.27 ± 0.72 (7)‡ 1.19 ± 0.28 (6)‡ 0.67 ± 0.13 (5)§
Heart function
Ejection fraction (%) Baseline 68 ± 6 (11) 70 ± 3 (6) 69 ± 6 (6)
Acute phase 45 ± 6* 43 ± 8* 37 ± 8*
Chronic phase 49 ± 6* 42 ± 12* 65 ± 8†§
Percent change 71% ± 9% 59% ± 16% 95% ± 10%§
LVEDP (mm Hg) Baseline 5.5 ± 4.8 (11) 8.8 ± 2.8 (6) 9.8 ± 2.9 (6)
Acute phase 8.2 ± 4.0 13.5 ± 6.9 13.2 ± 4.5
Chronic phase 13.0 ± 5.4*† 17.7 ± 11.6 7.2 ± 4.6
∆ change 7.5 ± 6.8 8.8 ± 12.6 –2.8 ± 4.4§
Mean aortic pressure 
(mm Hg) Baseline 112 ± 8 (11) 109 ± 7 (6) 115 ± 9 (6)
Acute phase 99 ± 11 95 ± 8 102 ± 9
Chronic phase 117 ± 23† 112 ± 20 102 ± 18
Heart rate (beats/min) Baseline 243 ± 48 (11) 252 ± 42 (6) 232 ± 29 (6)
Acute phase 226 ± 42 228 ± 27 213 ± 41
Chronic phase 260 ± 27 275 ± 41 267 ± 44†
Systemic indices
Body weight (kg) Baseline 3.43 ± 0.31 (7) 3.71 ± 0.19 (11) 3.49 ± 0.31 (6) 3.68 ± 0.28 (6)
Chronic phase 3.63 ± 0.32* 3.40 ± 0.26* 3.20 ± 0.28¶ 3.73 ± 0.27§
Percent change 106% ± 2% 92% ± 8%‡ 92% ± 7%‡ 102% ± 4%§
Renal blood flow 
(mL · min–1 · g–1) Baseline 4.55 ± 1.11 (11) 3.96 ± 0.71 (6) 3.97 ± 0.63 (6)
Acute phase 3.86 ± 1.03 3.22 ± 0.42 3.27 ± 0.49
Chronic phase 2.85 ± 0.45*† 3.10 ± 0.51 2.71 ± 0.64*
Percent change 68% ± 30% 80% ± 18% 70% ± 21%
Cerebral blood flow 
(mL · min–1 · g–1) Baseline 0.62 ± 0.16 (11) 0.53 ± 0.10 (6) 0.68 ± 0.09 (6) 
Acute phase 0.44 ± 0.16* 0.38 ± 0.07 0.46 ± 0.08*
Chronic phase 0.56 ± 0.18† 0.45 ± 0.14 0.57 ± 0.15
Percent change 93% ± 28% 86% ± 25% 84% ± 22%
The coronary arteries of all rabbits were injected with 15-µm microspheres to induce myocardial ischemia. Saline solution, Ad-lacZ, or Ad-VEGF was injected into
the coronary artery after the microsphere injection (sham-1, sham-2, and VEGF group, respectively). The above-described indices were measured immediately before,
immediately after, and 17 days after injection of the microspheres (baseline, acute phase, and chronic phase, respectively); Percent change, (Chronic phase/baseline)
× 100; ∆ change, Chronic phase – Baseline. The numbers of animals are indicated in parentheses. LVEDP, Left ventricular end-diastolic pressure. Data are means ±
SD. P < .05 versus baseline* and acute phase† (ANOVA for repeated measures with the Scheffé F test) and versus normal standard,‡ sham-1,§ and sham-2 groups
(ANOVA for factorial with the Scheffé F test). ¶P = .053 versus baseline (paired t test). 
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sham groups (P < .05, ANOVA, Table I). Histologic
analysis revealed multiple, small patchy infarctions
with inflammatory infiltrates surrounded by nonin-
farcted myocardium throughout the heart, but the
extent of the infarctions in the VEGF group was small-
er than in the sham groups (P = .02, Mann-Whitney
test, Fig 2, C and D). In the sham control rabbits, the
left side of the interventricular septum exposed to the
high-pressure chamber showed more marked infarction
than the right side, and the infarction area determined
semiquantitatively was more marked in the subendo-
cardial region of the left ventricular free wall than in
the subepicardial muscle (P = .01, Wilcoxon signed
rank sum test, Fig 2, C). 
Treatment with Ad-VEGF restored heart function. In
the chronic phase, the ejection fraction in the VEGF
group was restored to a sub-baseline value (95% ± 10%
of the baseline value), whereas in sham groups it
remained similar to the levels in the acute phase (P <
.05, ANOVA, Table I). LVEDP decreased within 17
days in the VEGF group but did not improve in the
sham groups. The degree of LVEDP recovery (chronic
phase value minus baseline value) was greater in the
VEGF group than in the sham groups (P < .05,
ANOVA, Table I).
Assessment of systemic functions showed that treat-
ment with Ad-VEGF partially prevented the body
weight loss caused by inducing ischemia. Four of the 6
rabbits in the VEGF group gained weight as did the
normal standard rabbits, whereas all animals in the
sham groups lost weight during the 17 days (P < .05,
ANOVA, Table I). Abnormal signs of increased vascu-
lar permeability, such as tissue edema and ascites, were
not observed in VEGF-treated rabbits. Cerebral blood
flow recovered to sub-baseline values, but the recovery
in renal blood flow was not enough in all 3 groups in
the chronic phase. No significant effect of Ad-VEGF
was seen in these 2 systemic perfusion indices. No his-
Fig 1. Angiograms of the ischemic heart. Contrast material was injected into the ascending aorta 16 days after
induction of ischemia. Opacified vessels around the apex are shown in the rabbits in the sham-1 group (A) and
VEGF group (B). The large and medium white arrows point to the peripheral portion of the left circumflex artery
and its first-order branches, respectively; the double white arrows to the peripheral portion of the left anterior
descending artery; the small black arrows to localized dense contrast region; and the large and small arrowheads
to the internal thoracic artery and its branches, respectively. Bar = 5 mm.
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tologic evidence of ischemia or pathologic changes,
including inflammation, was found in other major
organs (brain, kidney, and liver) in any of the groups.
No clear differences in any of the indices or morpho-
logic findings were seen between the sham-1 and
sham-2 groups.
Gene expression in vivo. Tissue levels of VEGF
were 44 ± 28 pg/mg protein in the heart and were below
the detection limit (5 pg/mg) in the brain, kidney, and
plasma in Ad-VEGF–treated animals 4 days after the
intracoronary injection (P < .05, heart vs brain, kidney,
and plasma, ANOVA, n = 4). In the sham-1 group (n =
4), VEGF levels in the heart were 7 ± 9 pg/mg (P = .04
vs VEGF group, unpaired t test), and those in the other
3 tissues were less than 5 pg/mg. The expression of
lacZ was confirmed in the vascular cell and the sur-
rounding tissue in the heart by X-Gal histostaining 4
days after the injection in the sham-2 group (n = 2, data
not shown). 
Discussion
New findings in this study.  In vivo gene transfer by
means of recombinant Ad-VEGF was an effective
approach to the treatment of microvascular ischemia.
When the animals were examined 17 ± 3 days later,
semi-selective injection of Ad-VEGF into the coronary
artery after induction of ischemia promoted coronary
angiogenesis (Table I, Fig 1, and Fig 2, A and B), ame-
liorated the degree of myocardial ischemia (Table I and
Fig 2, C and D), and restored heart function (Table I). 
Considerations in regard to the experimental
model. Chilian and colleagues25 reported that injec-
tion of a certain number of microspheres (25 µm in
diameter, 2 × 105/g myocardium) into the left circum-
flex artery abolished coronary vasodilator reserve but
maintained blood flow at rest in dogs. Under these
conditions, myocardial oxygen supply and demand is
unbalanced except at rest. In our model, the calculat-
ed number of microspheres was approximately 55%
(1.1 × 105/g myocardium) and their diameter was
smaller (15 µm), but the whole heart was involved.
The results in the preliminary study (paragraph 4 in
the “Methods” section) validated that our model is a
delayed infarction model rather than an acute infarc-
tion model. Histologic studies showed that small
patchy infarctions extended over all segments of the
heart but occurred predominantly in the inner region
of the left ventricle and that a large portion of the
myocardium was not necrotic (Fig 2, C). Because the
microspheres were injected while blood flow into the
descending aorta and bilateral carotid arteries was
stopped, precapillary arteriole plugging by micro-
spheres occurred semi-selectively in the heart, but not
in other tissues, except for the area perfused by the
subclavian arteries. The microsphere plugging of the
coronary arterial system induced microvascular
myocardial ischemia. The increased LVEDP,
decreased ejection fraction, and decreased body
weight constituted evidence of myocardial dysfunc-
tion. The 87% to 92% recovery of “mean” myocardial
flow does not always indicate substantial recovery in
myocardial perfusion and heart function.
In our recent experiments using microsphere plug-
ging in dogs,9,10 regional ischemic myocardial flow
was characterized by its large variability (analyzed
with synchrotron radiation: resolution 2-3 mg26) but
“mean” flow in the ischemic region was not different
from that in the normal region (analyzed with conven-
tional x-ray techniques: resolution 2-3 g). Furthermore,
this variability in flow was associated with contractile
deterioration and high tissue lactate content; that is, the
microsphere-plugging model produces substantial dis-
parity in flow distribution in milligram-order flow
analysis that cannot be detected by gram-order flow
analysis. In other words, small number of regions with
a markedly increased flow increased the mean value,
but substantial regions were still in the critical flow
range. Thus, the possibility that some regions with
markedly decreased flow decreased the mean value in
the acute phase cannot be ruled out. However, the con-
traction was worst in the acute phase.
The effects of angiogenic therapy have been reported
in several animal models in which myocardial ischemia
was induced by occluding the proximal left circumflex
artery with an ameroid constrictor.3,4,6,7 The advantage
of using the ameroid constrictor is that myocardial
ischemia develops gradually and resembles the most
common type of coronary artery disease seen in clini-
cal settings. Ischemia induced with an ameroid con-
strictor involves proximal segments of major coronary
artery branches; in contrast, our model involves multi-
ple peripheral coronary segments.
Amelioration of myocardial ischemia with Ad-
VEGF. The results of the present study clearly showed
that gene transfer of VEGF165 with an adenoviral vec-
tor increased myocardial VEGF level and improved
myocardial blood flow and intramyocardial vessel den-
sity. These results are evidence of promotion of angio-
genesis by Ad-VEGF. The increased intramyocardial
arterial (90-510 µm in diameter) and arteriolar (20-100
µm in diameter) density may, at least in part, be due to
a remodeling of smaller vessels, because the period for
examining the effect of Ad-VEGF (17 ± 3 days) was
obviously too short for new large vessels to form.
Therefore, the angiogenesis induced by injecting Ad-
VEGF into the ischemic heart in vivo in the present
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experiments was a primary event. A similar reaction
was observed around the internal thoracic artery (Fig 1,
B). This is due to “semi-selective” injection in which
both indium-labeled microspheres and adenovirus were
delivered to this artery via uninterrupted subclavian
arteries, as well as to the coronary arteries.
The angiogenesis induced by Ad-VEGF ameliorated
the degree of myocardial ischemia. The reduction of
lactate content and necrotic area in the myocardium
was related to the improvement of regional perfusion,
that is, the angiogenesis in the myocardium.
Amelioration of myocardial ischemia restored heart
function to a certain extent (reduction in LVEDP and
increase in ejection fraction). However, recovery in
systemic perfusion, such as cerebral and renal blood
flow, was not enough. As shown in Table I, the VEGF
group is characterized by reduced LVEDP (7.2 mm Hg
in mean, 73% of baseline) and slightly decreased renal
flow (70% of baseline). Relative cardiac output arbi-
trarily determined by percent change of renal flow
divided by percent change of LVEDP was 0.96
(70%/73%). These indices in the sham-1 (0.29) and
sham-2 groups (0.40) were obviously lower than the
VEGF value. Capillary leak induced by VEGF might
be related in part to reduction in preload. The reduction
in preload may have unloaded the ventricle and result-
Fig 2. Histologic examination of myocardium with microvascular ischemia in the rabbit. A and C, Sixteen days
after intracoronary injection of microspheres (sham-1 group). The infarction scores of the left and right sides of the
interventricular septum (IVS) are 3 and 2, respectively. B and D, Sixteen days after injection of microspheres and
Ad-VEGF (VEGF group). The infarction scores on both sides of the interventricular septum are 1. Arrowheads,
Intramyocardial arterioles (20-100 µm in diameter); arrows, arteries with a diameter of more than 100 µm; LVC,
left ventricular cavity; RVC, right ventricular cavity. Hematoxylin and eosin stain (A and B); azan stain (C and D).
Original magnifications ×6.1; bar = 1 mm.
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ed in improvement in ejection fraction. The lack of effi-
cacy of Ad-lacZ on ischemia demonstrated that the
angiogenesis was due to the gene transfer of VEGF165,
not the vector. 
On day 4 after the intracoronary injection of Ad-
VEGF, expression of VEGF gene was confirmed in the
heart by the analysis of tissue VEGF levels but not in
the periphery, namely, the brain, kidney, and plasma.
LacZ study also confirmed the gene expression in the
heart (data not shown). Since expression of the trans-
fected VEGF gene is limited to 2 to 3 weeks,27 we
killed the animals 14 to 21 days (mean 17 days) after
gene transfer. An acute inflammatory reaction has been
reported28,29 to be a drawback to the use of adenoviral
vectors. In our model, inflammatory changes were
observed only in the heart but not in the brain, kidney,
or liver. We could not distinguish the adenoviral
inflammation from the reaction to infarction. However,
the degree of inflammatory reactions in the sham-2
group was similar to that in the sham-1 group (rela-
tively moderate), and those in the VEGF group were
less severe. These results suggest that adenoviral vec-
tors were unlikely to be a main cause for inflammato-
ry changes in the heart. In addition, we could not find
tissue edema or ascites due to increased vascular per-
meability.
In summary, the present results indicate that in vivo
gene transfer of VEGF165 can be used to treat microvas-
cular myocardial ischemia that is unresponsive to con-
ventional therapies such as percutaneous transluminal
coronary angioplasty or coronary artery bypass grafting.
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